Skip to main content

Table 1 Baseline patient characteristics and medication use

From: Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

Characteristic Placebo (N = 1206) Apabetalone (N = 1212)
Age (years)a 62 (56–68) 62 (55–68)
Males (%) 74.0 74.8
Caucasian (%) 87.6 87.7
Body mass index (kg/m2) 30.3 ± 5.0 30.2 ± 4.8
Hypertension (%) 87.8 89.4
Dyslipidemia (%) 75.4 74.5
Current or ex-smoker (%) 10.4 12.1
Duration of diabetes (years) 8.7 ± 7.7 84. ± 7.6
Prior myocardial infarction (%) 14.7 14.4
Prior coronary revascularization (%) 21.2 21.4
History of heart failure (%) 14.8 15.1
History of atrial fibrillation (%) 7.2 7.0
History of chronic kidney disease (%) 4.6 5.4
Index ACS event
 STEMI (%) 39.0 38.6
 Non-STEMI (%) 35.4 34.2
 Unstable angina (%) 25.3 26.7
PCI for index ACS (%) 79.2 79.8
Time from index ACS to randomization (days)a 38 (25–62) 38 (25–63.5)
Medications
 Atorvastatin (%) 51.4 51.2
 Rosuvastatin (%) 48.6 48.8
 High-intensity statin (%) 90.5 89.9
 ACE inhibitor/angiotensin II receptor antagonist (%) 92.0 92.3
 Beta-blockers (%) 90.2 91.0
 Carvedilol, bisoprolol or nebivolol (%) 69.1 67.6
Anti-platelet agents (%) 99.1 98.7
 Dual anti-platelet agents (%) 88.3 87.2
Diuretics (%) 53.5 51.3
Mineralocorticoid receptor antagonists (%) 23.1 21.8
Sacubitril/valsartan 0.3 0.1
Diabetes medications
 Metformin (%) 82.0 83.3
 Insulin (%) 38.5 36.7
 Sulfonlyureas (%) 28.5 30.0
 DPP4 inhibitors (%) 14.8 14.9
 SGLT2 inhibitors (%) 12.3 12.4
 GLP1 receptor agonists (%) 3.7 3.4
  1. Clinical characteristics and medication use of patients treated with apabetalone or placebo. Results expressed as percentage, mean ± standard deviation or amedian (interquartile range)
  2. ACS acute coronary syndrome, DPP4 dipeptidyl peptidase 4, GLP1 glucagon like peptide 1, PCI percutaneous coronary intervention, SGLT2 sodium glucose transporter 2, STEMI ST segment myocardial infarction